Key Points
- COO Bryan Dechairo sold 3,413 shares at an average of $99.53 on Feb. 2 for $339,695.89, reducing his stake by 36.41% to 5,961 shares (≈$593k).
- The sale adds to a cluster of recent C‑suite insider sales (including the CEO and CFO), which may signal reduced near‑term insider conviction and concern for investors.
- Shares are trading down (opened $95.23, down ~3.8%), sit below the 50‑ and 200‑day moving averages, and carry a market cap of ~$2.75B with a consensus analyst rating of "Moderate Buy" and a $138.13 average price target.
GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) COO Bryan Dechairo sold 3,413 shares of the company's stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $99.53, for a total transaction of $339,695.89. Following the completion of the sale, the chief operating officer owned 5,961 shares of the company's stock, valued at approximately $593,298.33. The trade was a 36.41% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
GeneDx Trading Down 3.8%
NASDAQ:WGS opened at $95.23 on Wednesday. GeneDx Holdings Corp. has a 12 month low of $55.17 and a 12 month high of $170.87. The company has a current ratio of 2.71, a quick ratio of 2.59 and a debt-to-equity ratio of 0.18. The firm's 50 day moving average is $131.03 and its 200 day moving average is $125.13. The stock has a market capitalization of $2.75 billion, a PE ratio of 1,058.11 and a beta of 2.00.
Key Headlines Impacting GeneDx
Here are the key news stories impacting GeneDx this week:
- Positive Sentiment: Analyst consensus remains favorable — the stock carries a "Moderate Buy" consensus and several firms have recently reaffirmed or raised price targets, which supports longer-term upside. Analyst Consensus
- Neutral Sentiment: Institutional ownership is sizable (~61.7%) with modest quarter-to-quarter adjustments by some funds; that large institutional base can dampen short-term volatility but also concentrates moves when sentiment shifts. Institutional & Insider Summary
- Neutral Sentiment: Reported short-interest data in the recent update is effectively zero/insignificant (likely a data anomaly), so short-covering dynamics are not a clear driver of today’s move. No clear short squeeze risk is indicated.
- Negative Sentiment: Multiple insider sales by senior executives: COO Bryan Dechairo sold 3,413 shares (~$339.7k) and CEO Katherine Stueland sold 1,653 shares (both late January transactions disclosed in SEC filings). Such clustered insider selling by C‑suite members can signal to the market a reduced near-term insider conviction. COO Form 4 CEO Form 4
- Negative Sentiment: CFO Kevin Feeley also sold shares (317 shares reported), adding to the pattern of insider sales and amplifying investor concern about executive liquidity events. CFO Sale
- Negative Sentiment: Technical picture is unfavorable: the share price sits well below the 50-day and 200-day moving averages cited in recent summaries, which can prompt momentum selling from traders using technical triggers. Price & Technicals
Institutional Trading of GeneDx
Institutional investors have recently bought and sold shares of the company. Jones Financial Companies Lllp raised its stake in shares of GeneDx by 664.3% in the third quarter. Jones Financial Companies Lllp now owns 214 shares of the company's stock worth $25,000 after purchasing an additional 186 shares during the last quarter. Quarry LP grew its position in GeneDx by 248.8% in the 3rd quarter. Quarry LP now owns 293 shares of the company's stock worth $32,000 after purchasing an additional 209 shares during the period. Gordian Capital Singapore Pte Ltd purchased a new stake in GeneDx during the 3rd quarter valued at $65,000. AlphaQuest LLC lifted its holdings in shares of GeneDx by 351.5% during the 2nd quarter. AlphaQuest LLC now owns 763 shares of the company's stock valued at $70,000 after buying an additional 594 shares during the period. Finally, Tower Research Capital LLC TRC boosted its stake in shares of GeneDx by 479.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,818 shares of the company's stock worth $168,000 after buying an additional 1,504 shares during the last quarter. 61.72% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of research analysts have recently commented on WGS shares. Wells Fargo & Company set a $155.00 price target on shares of GeneDx and gave the company an "equal weight" rating in a research report on Monday, December 15th. BTIG Research upped their target price on GeneDx from $165.00 to $200.00 and gave the stock a "buy" rating in a research note on Friday, December 12th. Weiss Ratings reiterated a "sell (d)" rating on shares of GeneDx in a research report on Wednesday, January 21st. Canaccord Genuity Group boosted their price objective on GeneDx from $160.00 to $170.00 and gave the stock a "buy" rating in a report on Monday, December 22nd. Finally, Guggenheim reaffirmed a "buy" rating and issued a $170.00 target price (up from $115.00) on shares of GeneDx in a research note on Wednesday, October 29th. Six analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $138.13.
Read Our Latest Stock Analysis on WGS
About GeneDx
(
Get Free Report)
GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx's laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.
Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
